



4. Framatome is engaged in the business of designing and manufacturing nuclear fuel assemblies for commercial nuclear reactors. Within the United States, there are two additional firms that design and manufacture nuclear fuel for commercial nuclear reactors and there are several other companies outside of the United States that engage in the same business as Framatome. Competition among these companies including Framatome is fierce and manufacturing costs of the nuclear fuel are critical to the maintenance of market share and to the growth of market share among utility customers.

5. The application for the License Amendment utilizing “Framatome TN-B1 Docket No. 71-9372 Safety Analysis Report”, FS1-0014159 contains commercial information of a confidential nature that is not available in public sources or available to the public. This information contained in this report is commercial and confidential because it reveals specific information about the Framatome Richland manufacturing facility relative to its production throughput. All of this information can be used by competitors to gain undue insight into Framatome’s commercial relationships, probable cost structure, operations and business.

6. Framatome Inc. will suffer considerable competitive harm if the contents of the license amendment package are made available to Framatome domestic and international competitors. Finally, this material cannot be reasonably segregated from other material which may not meet the criteria set forth in 10 CFR § 2.390.

9. The foregoing statements are true and correct to the best of my knowledge, information, and belief.

Dated this 28<sup>th</sup> day of January 2022



\_\_\_\_\_  
Timothy J. Tate, Manager  
Environmental, Health, Safety and Licensing  
Framatome Inc.

SUBSCRIBED before me this 28<sup>th</sup> day of January 2022.



\_\_\_\_\_  
Debbie Coyner  
NOTARY PUBLIC, STATE OF WASHINGTON  
MY COMMISSION EXPIRES: April 26, 2022

